Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study was to evaluate the efficacy and safety of high-dose dual therapy compared with furazolidone-based quadruple therapy as a rescue treatment for helicobacter pylori infection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Amoxicillin; Bismuth; Esomeprazole; Furazolidone; Potassium Citrate

Criteria

Inclusion Criteria:

• The patients who were diagnosed with persistent H. pylori infection and had previously failed one or more courses of eradication therapies that included amoxicillin, clarithromycin, or nitroimidazole.

Exclusion Criteria:

• Age < 18 years old.

• The time frame was less than 6 months from the previous eradication therapy.

• The previous eradication therapy included furazolidone.

• Allergic to the medication.

• Pregnant or lactating women.

• Comorbidities of severe conditions like hepatic, renal or cardiorespiratory diseases or malignancy.

• Administration of antibiotics, bismuth or PPI in the preceding 4 weeks.